VPS16 core subunit of CORVET and HOPS complexesGenealiases: DYT30 · hVPS16
Q-omics provides the consensus-scored VPS16 profile across patient tissues and cancer cell-line models. VPS16 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, VPS16 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, VPS16 protein abundance shows 21,203 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight MESO, HNSC, and PDAC as cancer lineages where VPS16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VPS16 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VPS16 survival associations across molecular data types. VPS16 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VPS16 RNA expression–survival associations across cancer types. High VPS16 expression shows unfavorable associations in MESO, LGG, LIHC, KICH, UVM and COAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for VPS16 RNA expression.
This table summarizes VPS16 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for VPS16. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VPS16 shows lower tumor expression in THCA and higher tumor expression in HNSC, KIRC, LIHC, STAD and BRCA. The HNSC box plot shows higher VPS16 RNA expression in tumor versus normal tissue (log2 FC = +0.797, t-test p < 0.001).
This table shows molecular features associated with VPS16 in patient tissues and cancer cell lines. In patient samples, VPS16 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, VPS16 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and UPPER_AERODIGESTIVE_TRACT.
